🔎 Trials Near Me

Akèy › Kansè nan tete › Ohio › Akron

Etid klinik pou Kansè nan tete nan Akron, OH

13 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Akron (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton · 7 mi lwen
  • ak 1 plis
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Ap rekriteFaz 2
  • Gabrail Cancer Center, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ap rekriteFaz 3
  • Cleveland Clinic Akron General, Akron
  • Gabrail Cancer Center, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Ap rekriteFaz 3
  • Summa Health System - Akron Campus, Akron
  • Summa Health System - Barberton Campus, Barberton · 7 mi lwen
  • Summa Health Medina Medical Center, Medina · 18 mi lwen
  • ak 2 plis
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Ap rekriteFaz 3
  • Gabrail Cancer & Research Center, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612

Integrated Cancer Repository for Cancer Research

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Aultman Hospital, Canton · 21 mi lwen
  • Aultman Alliance Community Hospital, Alliance · 24 mi lwen
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Ap rekriteFaz 3
  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton · 7 mi lwen
  • ak 4 plis
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Ap rekriteFaz 1/2
  • Gabrail Cancer Research Center, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05735080

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Ap rekriteEtid obsèvasyon
  • Tri-County Hematology & Oncology Associates, Inc., Massillon · 20 mi lwen
  • Cleveland Clinic Mercy Hospital, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT05974150

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Ap rekriteEtid obsèvasyon
  • Aultman Timken Family Cancer Center, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06401421

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Ap rekriteFaz 3
  • Cleveland Clinic Akron General, Akron
  • University Hospitals Sharon Health Center, Wadsworth · 12 mi lwen
  • Aultman Health Foundation, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Ap rekriteEtid obsèvasyon
  • Akron General Medical Center, Akron
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2025 · NCT03053193

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Ap rekriteFaz 2
  • Gabrail Cancer Center Research, Canton · 21 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692

Etid Kansè nan tete nan lòt vil

Lòt etid nan Akron

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.